Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DXR
stocks logo

DXR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast DXR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXR is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast DXR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXR is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.850
sliders
Low
22.00
Averages
22.00
High
22.00
Current: 12.850
sliders
Low
22.00
Averages
22.00
High
22.00
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$25 → $25
2025-03-17
Reason
Ascendiant Capital
Edward Woo
Price Target
$25 → $25
2025-03-17
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Daxor Corp (DXR.O) is 2.57, compared to its 5-year average forward P/E of 16.15. For a more detailed relative valuation and DCF analysis to assess Daxor Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
16.15
Current PE
2.57
Overvalued PE
36.54
Undervalued PE
-4.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.88
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
37.33
Undervalued EV/EBITDA
-11.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
249.38
Current PS
0.00
Overvalued PS
463.34
Undervalued PS
35.41
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

DXR News & Events

Events Timeline

(ET)
2025-11-25
08:02:38
Daxor reveals plans to extend its BVA platform to three additional locations.
select
2025-09-30 (ET)
2025-09-30
08:22:56
Daxor Introduces FDA-Approved BVA Analyzer at HFSA Conference
select
2025-09-04 (ET)
2025-09-04
08:06:54
Daxor's Blood Volume Assessment Confirmed for Patients with COVID and Sepsis
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
08-12Newsfilter
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available

  • Daxor Corporation Milestone: Daxor Corporation celebrated the FDA 510(k) clearance of its next-generation, hand-held Blood Volume Analyzer (BVA) during a Nasdaq Closing Bell Ceremony on August 8, 2025.

  • Impact on Healthcare: The BVA technology aims to address the critical issue of accurately measuring blood volume, which can lead to improved patient outcomes and efficiencies in healthcare management, particularly for conditions like heart failure.

[object Object]
Preview
9.5
08-08TipRanks
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories

  • Earnings Reports: Investors are receiving a variety of news on Thursday, particularly focused on earnings reports and other significant announcements in the stock market.

  • TipRanks Daily Wrap-Up: TipRanks provides a daily summary to help investors stay informed about the most important stock market headlines and developments.

[object Object]
Preview
9.0
08-07TipRanks
Why Is Daxor Stock (DXR) Up 20% Today?

  • Daxor's FDA Clearance: Daxor's stock surged after receiving FDA clearance for its new Blood Volume Analyzer, which allows for accurate blood volume measurement and improved fluid management in patients with complex conditions.

  • Stock Performance and Analyst Rating: Following the news, Daxor's stock rose significantly, with heavy trading activity; however, Wall Street coverage remains limited, and an AI analyst rates the stock as Neutral due to mixed performance indicators.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Daxor Corp (DXR) stock price today?

The current price of DXR is 12.85 USD — it has increased 1.58 % in the last trading day.

arrow icon

What is Daxor Corp (DXR)'s business?

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

arrow icon

What is the price predicton of DXR Stock?

Wall Street analysts forecast DXR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXR is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Daxor Corp (DXR)'s revenue for the last quarter?

Daxor Corp revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Daxor Corp (DXR)'s earnings per share (EPS) for the last quarter?

Daxor Corp. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Daxor Corp (DXR)'s fundamentals?

The market is revising No Change the revenue expectations for DXR for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 16.18%.
arrow icon

How many employees does Daxor Corp (DXR). have?

Daxor Corp (DXR) has 750 emplpoyees as of December 05 2025.

arrow icon

What is Daxor Corp (DXR) market cap?

Today DXR has the market capitalization of 64.05M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free